SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing significant speculative activity and divided community sentiment, with many anticipating a 'meme coin season' rally and closely watching for potential integration into X's financial services. Traders are actively debating bullish targets and bearish reversals, fueling volatile price action.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is experiencing a strong upward trend, sparking community excitement around a potential meme coin season, with many calling to "HODL" for significant gains, especially following a notable reduction in its circulating supply. It's often highlighted as the "alpha frog" leading a broader "three-frog narrative" in the current crypto rebound.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT &amp; Merchandise Marketplace.

Floki Token

Floki is trending amidst renewed community excitement, largely driven by recent social media attention from Elon Musk and its pioneering ETP launch in Europe, positioning it as an evolving memecoin with growing institutional visibility. While some investors are embracing the hype, many long-term holders emphasize its expanding ecosystem, including a play-to-earn game and AI integrations, as core to its future in the altcoin market.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG Crypto is trending amid reports of Coinbase listing support, sparking intense community discussion about its Bitcoin-native fundamentals, fair launch, and potential to become a leading memecoin by challenging incumbents.

TOSHI

TOSHI is trending strongly across crypto platforms, with the community enthusiastically highlighting bullish chart patterns and rising volume amid renewed optimism for an "alt season," further solidifying its narrative as the "face of Base" ecosystem.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

PENGU is trending due to the Pudgy Penguins brand's real-world expansion and high-profile partnerships, including its visibility on the Las Vegas Sphere, an NHL collaboration, and retail presence with toys. While many in the community highlight its differentiating utility and long-term potential, others express frustration over its price performance given these developments.

Anheuser-Busch InBev SA/NV operates as a holding company, which engages in the manufacture and distribution of alcoholic and non-alcoholic beverages. It operates through the following geographical segments: North America, Middle Americas, South America, EMEA, Asia Pacific, and Global Export and Holding Companies. The company was founded on August 2, 1977 and is headquartered in Leuven, Belgium.

Anheuser-Busch InBev SA/NV - ADR

Anheuser-Busch InBev

Anheuser-Busch InBev is trending after a Q4 earnings report that saw profits exceed expectations, driven by strong premium brand performance, despite a revenue shortfall and slight beer volume declines; this mixed outcome fuels community debate on its long-term growth and resilience against changing consumer trends and recent strategic partnerships.

Miller Industries, Inc. (Tennessee) engages in the manufacture of vehicle towing and recovery equipment. Its products include car carriers, light duty, heavy duty, rotators, and special transport. The firm markets its products under the brand names of Century, Challenger, Holmes, Champion, Eagle, Titan, Jige, Boniface, Vulcan, and Chevron. The company was founded by William G. Miller in 1990 and is headquartered in Ooltewah, TN.

Miller Industries Inc.

Miller Industries is sharply declining after reporting an earnings miss for its latest quarter and issuing significantly lower revenue and EPS guidance for the upcoming fiscal year, prompting widespread community discussion and concern about its future performance.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending due to massive whale accumulation and a surge in futures activity, sparking community excitement about the potential start of a new meme coin season and a broader altcoin market supercycle.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining significant attention due to its partnership with the U.S. Commerce Department to publish economic data on-chain, cementing its role as a leading oracle for Real World Assets (RWAs). The community is actively discussing its fundamental utility and revenue-backed token buyback program, contrasting it with meme coins and anticipating substantial growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of "Hold" by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have been given a consensus recommendation of "Hold" by the seventeen analysts that are presently covering the company, Marketbeat...

Hims & Hers Health (NYSE:HIMS) Hits New 52-Week Low - Here's Why

Hims & Hers Health (NYSE:HIMS) Sets New 1-Year Low - Here's Why...

Hims & Hers Strengthens Integrated Personalized Digital Care Platform

HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5 million.

Novo CEO blasts 'mass compounding' of GLP-1 drugs as safety battle escalates

GLP-1 weight-loss drugs are now the focus of a heated legal battle, with a leading drugmaker warning that copycat versions pose a risk to patient safety.'When you go and try to source raw materials...

HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?

Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin pressures raise concerns.

<ul class="summary-bullets"><li>The three-day rout was driven by Novo Nordisk’s lawsuit and an FDA crackdown on compounded GLP-1 drugs.</li><li>Deutsche Bank and Canaccord cut price targets on HIMS but pointed to 70%–80% upside from current levels.</li><li>Canaccord said the selloff has already stripped out much of the value tied to compounded semaglutide sales.&nbsp;</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) are drawing renewed scrutiny after a brutal three-day selloff tied to regulatory pressure and legal action around compounded GLP-1 drugs, with at least one Wall Street firm arguing that much of the downside risk may now be reflected in the stock.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> fell 11% on Tuesday, extending its losing streak to an eighth straight session, as the FDA crackdown and Novo Nordisk’s lawsuit accelerated an already ongoing selloff.&nbsp;<h2 class="st-heading-2">Wall Street Sees Legal Risk Largely Priced In</h2>Deutsche Bank lowered the price target on Hims &amp; Hers to $31 from $42, implying an upside of about 80% from the stock’s last close, while reiterating a ‘Hold’ rating. The brokerage said Hims is “under siege” following the abrupt reversal of its GLP-1 pill launch.Canaccord was slightly more optimistic. The firm lowered its price target to $30 from $68, implying roughly 74% upside from current levels, while maintaining a ‘Buy’ rating. Canaccord said Novo Nordisk’s lawsuit adds “another layer of operational uncertainty,” but argued that the three-day share selloff has “implicitly removed” most of the value tied to compounded semaglutide sales. As a result, the firm believes a significant portion of the legal risk may already be priced into the stock.<h2 class="st-heading-2">FDA Crackdown And Novo Lawsuit Hit Hims GLP-1 Push</h2>Novo Nordisk said on Monday it has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">filed a lawsuit</a> seeking a permanent ban on Hims’ sales of compounded semaglutide products, alleging patent infringement and unlawful mass marketing of unapproved versions of Wegovy and Ozempic.“Hims &amp; Hers is mass marketing unapproved knock-off versions of Wegovy and Ozempic that evade the FDA’s gold-standard review process,” said Novo Nordisk senior vice president and general counsel John F. Kuckelman, calling the practice “dangerous and deceptive.”The legal action followed a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-volatility-retail-bulls-vs-bears-after-pill-halt/cZbHmsDR48g">warning</a> from the U.S. Food and Drug Administration, which said it would crack down on GLP-1 active pharmaceutical ingredients used in non-approved compounded drugs. The FDA said it may restrict access to such ingredients and refer violations to the Department of Justice, citing safety and quality concerns.In response, Hims said it would stop offering its $49 compounded semaglutide pill just days after launching the product, saying it had held “constructive conversations” with industry stakeholders.<h2 class="st-heading-2">Wall Street View On HIMS Downside Scenarios</h2>Earlier this week, Citi cut its price target on Hims &amp; Hers to $16.50 from $30 and maintained a ‘Sell’ rating, warning that the company’s GLP-1 strategy was “risky and aggressive.” Citi said its target reflects a 25% probability of Hims losing all weight-loss drug sales, a 60% base-case scenario of losing half of those sales, and only a 15% bull-case outcome with limited GLP-1 downside.Bank of America Securities also trimmed its target to $21 from $26 and reiterated an ‘Underperform’ rating. The firm noted that the FDA did not distinguish between oral and injectable GLP-1 products in its warning, raising the risk that regulatory scrutiny could extend to Hims’ injectable semaglutide offerings.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for HIMS was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_1f0284a84d.webp" alt="hims ss.png" width="968" height="143"><figcaption>HIMS sentiment and message volume as of February 11 | Source: Stocktwits</figcaption></figure>One user said, “may be it will take couple of years to go $60 again . It did 5 times last year but this time its different. This needs time.”<stembedurl>https://stocktwits.com/nostoplosss/message/644639747</stembedurl>Another user said that, with earnings approaching on Feb. 23, the stock could see a rebound. They added that “stock is already on lowest bottom u can imagine , load the boat before its too late”<stembedurl>https://stocktwits.com/expato14/message/644637544</stembedurl>HIMS stock has declined 61% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In?

Deutsche Bank and Canaccord cut price targets on HIMS but pointed to 70%-80% upside from current levels.

Equity

<ul class="summary-bullets"><li>GDNF outperformed semaglutide, the active ingredient in Wegovy and Ozempic, across several key measures, Hoth said.</li><li>The 12-week study showed that female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, whereas semaglutide showed no meaningful effect.</li><li>The company said GDNF reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease.</li></ul>Hoth Therapeutics (HOTH), on Tuesday, announced preclinical results from a Veterans Administration-backed study evaluating glial cell-derived neurotrophic factor (GDNF) as a potential treatment for obesity and metabolic-associated steatotic liver disease (MASLD).The company stated that in a head-to-head comparison, GDNF outperformed semaglutide, the active ingredient in weight-loss drugs such as Wegovy and Ozempic, across several key measures, including weight control, glucose tolerance, liver weight reduction, and adipose tissue control.<a href="https://stocktwits.com/symbol/HOTH">HOTH shares</a> were up over 5% in pre-market trading but reversed gains after the opening bell, trading 6% lower.<h2 class="st-heading-2">What Did The 12-Week Study Show?</h2>During the 12-week study, female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, eventually entering a stabilization phase, whereas semaglutide showed no meaningful effect. Researchers noted that higher doses or longer durations could amplify GDNF’s effects.GDNF also normalized fasting glucose levels and improved responses to glucose challenges. Additionally, the therapy reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease, a common issue with obesity.“These results are a monumental step forward for Hoth and the fight against obesity. GDNF not only matched but exceeded semaglutide in critical areas, opening doors to a new era of safer, more effective therapies,” said Robb Knie, CEO of Hoth Therapeutics.<h2 class="st-heading-2">What’s Next?</h2>Hoth plans additional studies on liver pathology, lipid content, and gene and protein expression to better understand GDNF’s mechanism, with clinical trials targeted for 2027.Weight-loss drugs have become a central focus for the pharmaceutical industry, driving revenue growth for leaders like Eli Lilly and Novo Nordisk as other companies race to enter the booming market.The segment has been under regulatory spotlight in the aftermath of Hims &amp; Hers launching a compounded version of Wegovy last week, which the company has since withdrawn following legal notices from NOVO and the U.S. Food and Drug Administration.&nbsp;&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment turned ‘bullish’ from ‘neutral’ a day earlier, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/HOTH_jpg_40deb046fb.webp" alt="HOTH.jpg">One user called for patience amid the intraday decline.<stembedurl>https://stocktwits.com/Tom678/message/644546402</stembedurl>HOTH shares are down around 21% so far this year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/why-did-azi-stock-reverse-gains-in-premarket/cZbUIHFR4Yy">AZI Stock Reverses Early Gains To Slump 30% In Pre-Market – What Happened?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide

NVO shares jump 3.6% after Hims & Hers halts compounded semaglutide following an FDA warning and patent lawsuit.

Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit

Hims & Hers Health (NYSE:HIMS), a direct-to-consumer telehealth platform, closed Monday at $19.33, down 16.03%. The stock dropped as news of a lawsuit from Novo Nordisk (NYSE:NVO) came on top of...

Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.33, denoting a -16.05% move from the preceding trading day.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Stocktwits

Stocktwits Polls

Hims & Hers Health Inc

Traders are intently following the legal disputes surrounding compounded GLP-1 medications, positioning HIMS as a disruptor against traditional pharma giants like Novo Nordisk.

With high short interest and deeply oversold technicals, many expect a major short squeeze to propel the stock higher despite recent price declines.

Despite significant price drops, many investors are calling a bottom, citing deeply oversold RSI levels and encouraging Dollar-Cost Averaging as the stock trades in the mid-teens.

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HIMS News

HIMSHims & Hers Health Inc